Phasing out the pre-transplant cytotoxicity crossmatch: Are we missing something?
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Jornal Brasileiro de Nefrologia |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002021000300365 |
Resumo: | Abstract Introduction: The anti-human globulin-enhanced complement-dependent cytotoxicity crossmatch (AHG-CDCXM) assay has been used to assess the presence of donor-specific antibodies (DSA) in recipient’s serum before kidney transplantation. The flow cytometric crossmatch (FCXM) assay was first introduced as an additional test. The aim of this study was to clinically validate the single use of the FCXM assay. Methods: This study compared the outcomes of a cohort of kidney transplant patients that underwent FCXM only (FCXM group) versus a cohort of kidney transplant patients that underwent AHG-CDCXM (control group). Results: Ninety-seven patients in the FCXM group and 98 controls were included. All crossmatches in the control group were negative. One patient in the FCXM group had a positive B cell crossmatch. One year after transplantation, there were no significant differences in patient survival (p = 0.591) and graft survival (p = 0.692) between the groups. Also, no significant difference was found in the incidence of Banff ≥ 1A acute cellular rejection episodes (p = 0.289). However, acute antibody-mediated rejections occurred in 3 controls (p = 0.028). Conclusion: The results showed that discontinuing the AHG-CDCXM assay does not modify the clinical outcomes in a 1-year follow-up. |
id |
SBN-1_e09069431d5b376facfdb6a4977b2ddf |
---|---|
oai_identifier_str |
oai:scielo:S0101-28002021000300365 |
network_acronym_str |
SBN-1 |
network_name_str |
Jornal Brasileiro de Nefrologia |
repository_id_str |
|
spelling |
Phasing out the pre-transplant cytotoxicity crossmatch: Are we missing something?Flow CytometryCytotoxicity Tests, ImmunologicGraft RejectionTransplante.Abstract Introduction: The anti-human globulin-enhanced complement-dependent cytotoxicity crossmatch (AHG-CDCXM) assay has been used to assess the presence of donor-specific antibodies (DSA) in recipient’s serum before kidney transplantation. The flow cytometric crossmatch (FCXM) assay was first introduced as an additional test. The aim of this study was to clinically validate the single use of the FCXM assay. Methods: This study compared the outcomes of a cohort of kidney transplant patients that underwent FCXM only (FCXM group) versus a cohort of kidney transplant patients that underwent AHG-CDCXM (control group). Results: Ninety-seven patients in the FCXM group and 98 controls were included. All crossmatches in the control group were negative. One patient in the FCXM group had a positive B cell crossmatch. One year after transplantation, there were no significant differences in patient survival (p = 0.591) and graft survival (p = 0.692) between the groups. Also, no significant difference was found in the incidence of Banff ≥ 1A acute cellular rejection episodes (p = 0.289). However, acute antibody-mediated rejections occurred in 3 controls (p = 0.028). Conclusion: The results showed that discontinuing the AHG-CDCXM assay does not modify the clinical outcomes in a 1-year follow-up.Sociedade Brasileira de Nefrologia2021-09-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002021000300365Brazilian Journal of Nephrology v.43 n.3 2021reponame:Jornal Brasileiro de Nefrologiainstname:Sociedade Brasileira de Nefrologia (SBN)instacron:SBN10.1590/2175-8239-jbn-2019-0222info:eu-repo/semantics/openAccessAbud,JamilePupo,Bruna Brasil DalSilva,Cynthia daKeitel,ElizeteGarcia,Valter DuroManfro,Roberto CerattiNeumann,Jorgeeng2021-11-05T00:00:00Zoai:scielo:S0101-28002021000300365Revistahttp://www.bjn.org.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||jbn@sbn.org.br2175-82390101-2800opendoar:2021-11-05T00:00Jornal Brasileiro de Nefrologia - Sociedade Brasileira de Nefrologia (SBN)false |
dc.title.none.fl_str_mv |
Phasing out the pre-transplant cytotoxicity crossmatch: Are we missing something? |
title |
Phasing out the pre-transplant cytotoxicity crossmatch: Are we missing something? |
spellingShingle |
Phasing out the pre-transplant cytotoxicity crossmatch: Are we missing something? Abud,Jamile Flow Cytometry Cytotoxicity Tests, Immunologic Graft Rejection Transplante. |
title_short |
Phasing out the pre-transplant cytotoxicity crossmatch: Are we missing something? |
title_full |
Phasing out the pre-transplant cytotoxicity crossmatch: Are we missing something? |
title_fullStr |
Phasing out the pre-transplant cytotoxicity crossmatch: Are we missing something? |
title_full_unstemmed |
Phasing out the pre-transplant cytotoxicity crossmatch: Are we missing something? |
title_sort |
Phasing out the pre-transplant cytotoxicity crossmatch: Are we missing something? |
author |
Abud,Jamile |
author_facet |
Abud,Jamile Pupo,Bruna Brasil Dal Silva,Cynthia da Keitel,Elizete Garcia,Valter Duro Manfro,Roberto Ceratti Neumann,Jorge |
author_role |
author |
author2 |
Pupo,Bruna Brasil Dal Silva,Cynthia da Keitel,Elizete Garcia,Valter Duro Manfro,Roberto Ceratti Neumann,Jorge |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Abud,Jamile Pupo,Bruna Brasil Dal Silva,Cynthia da Keitel,Elizete Garcia,Valter Duro Manfro,Roberto Ceratti Neumann,Jorge |
dc.subject.por.fl_str_mv |
Flow Cytometry Cytotoxicity Tests, Immunologic Graft Rejection Transplante. |
topic |
Flow Cytometry Cytotoxicity Tests, Immunologic Graft Rejection Transplante. |
description |
Abstract Introduction: The anti-human globulin-enhanced complement-dependent cytotoxicity crossmatch (AHG-CDCXM) assay has been used to assess the presence of donor-specific antibodies (DSA) in recipient’s serum before kidney transplantation. The flow cytometric crossmatch (FCXM) assay was first introduced as an additional test. The aim of this study was to clinically validate the single use of the FCXM assay. Methods: This study compared the outcomes of a cohort of kidney transplant patients that underwent FCXM only (FCXM group) versus a cohort of kidney transplant patients that underwent AHG-CDCXM (control group). Results: Ninety-seven patients in the FCXM group and 98 controls were included. All crossmatches in the control group were negative. One patient in the FCXM group had a positive B cell crossmatch. One year after transplantation, there were no significant differences in patient survival (p = 0.591) and graft survival (p = 0.692) between the groups. Also, no significant difference was found in the incidence of Banff ≥ 1A acute cellular rejection episodes (p = 0.289). However, acute antibody-mediated rejections occurred in 3 controls (p = 0.028). Conclusion: The results showed that discontinuing the AHG-CDCXM assay does not modify the clinical outcomes in a 1-year follow-up. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-09-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002021000300365 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002021000300365 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/2175-8239-jbn-2019-0222 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Nefrologia |
publisher.none.fl_str_mv |
Sociedade Brasileira de Nefrologia |
dc.source.none.fl_str_mv |
Brazilian Journal of Nephrology v.43 n.3 2021 reponame:Jornal Brasileiro de Nefrologia instname:Sociedade Brasileira de Nefrologia (SBN) instacron:SBN |
instname_str |
Sociedade Brasileira de Nefrologia (SBN) |
instacron_str |
SBN |
institution |
SBN |
reponame_str |
Jornal Brasileiro de Nefrologia |
collection |
Jornal Brasileiro de Nefrologia |
repository.name.fl_str_mv |
Jornal Brasileiro de Nefrologia - Sociedade Brasileira de Nefrologia (SBN) |
repository.mail.fl_str_mv |
||jbn@sbn.org.br |
_version_ |
1752122066965889024 |